S
S

Sobi

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Elia Group, Koninklijke Ahold, Oxford Instruments

EUROPE RESEARCH ROUNDUP-Elia Group, Koninklijke Ahold, Oxford Instruments Nov 15 (Reuters) - ṄSecurities analysts revised their ratings and price targets on several European companies, including Elia Group, Koninklijke Ahold and Oxford Instruments, on Wednesday. HIGHLIGHTS * Compass Group CPG.L : Deutsche Bank raises to buy from hold * Elia Group SA ELI.BR : Citigroup raises to buy from neutral * Koninklijke Ahold AD.AS : Morgan Stanley cuts to equal-weight from overweight * Oxford Instruments
B
B
C
C
H
H
I
I
J
K
N
O
P
R
R
S
S
T
V
A
E
I
N
R

AstraZeneca prioritizes US for RSV drug amid surge in cases

AstraZeneca prioritizes US for RSV drug amid surge in cases By Patrick Wingrove and Maggie Fick NEW YORK, Nov 10 (Reuters) - AstraZeneca AZN.L on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in infants and toddlers, as a surge of cases is outpacing supply.
A
S
S

Brazilian lawyer pleads guilty to insider trading while at Gibson Dunn law firm

Brazilian lawyer pleads guilty to insider trading while at Gibson Dunn law firm By David Thomas Nov 1 (Reuters) - A Brazilian lawyer pleaded guilty in U.S. court on Wednesday to insider trading after profiting off information about a $1.7 billion deal involving a client of his former law firm, Gibson, Dunn & Crutcher. Romero Cabral da Costa Neto, 33, entered his guilty plea in Washington, D.C., federal court, two months after his arrest .
S

European shares rise as bond yields retreat, Big Pharma rallies

UPDATE 2-European shares rise as bond yields retreat, Big Pharma rallies For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window German economy shrinks slightly in Q3 Sanofi recovers, boosts healthcare stocks ArcelorMittal falls, confirms talks to nationalize Kazakh unit HSBC slides as Q3 profit disappoints STOXX 600 up 0.4% Updated at 1648 GMT By Ankika Biswas and Bansari Mayur Kamdar Oct 30 (Reuters) - European shares began the week on a stron
A
D
H
I
S
S
E
F
U
G

Sobi rises on Q3 beat driven by Beyfortus, key products

BUZZ-Sobi rises on Q3 beat driven by Beyfortus, key products ** Shares in drugmaker Swedish Orphan Biovitrum (SOBI) SOBIV.ST rise more than 4% after its Q3 results beat expectations ** Its quarterly revenue came to SEK 5.17 bln ($462.85 mln), beating the IBES estimate of SEK 4.52 bln with Haematology and Immunology sales rising year-on-year ** Also
S
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.